Stakeholders
-
Amgen (US) (United States of America)
-
AstraZeneca (UK) (United Kingdom)
-
Briston-Myers Squibb (US) (United States of America)
-
CODE (USA) (United States of America)
-
IQVIA (US) (United States of America)
-
Lilly (US) (United States of America)
-
Merck Sharp & Dohme (US) (United States of America)
-
Pfizer (US) (United States of America)
-
Ecco - European Cancer Organisation (Belgium) (Belgium)
Strategic Goals
To drive innovation and support improvements in cancer care, and address information gaps by providing timely information on anti-cancer medicine use back to healthcare systems. It also aims to facilitate new models of access, and to help address the challenges of financial sustainability by providing information on how anti-cancer medicines are actually used in clinical practice
Solutions Developed / Used
With CODE, participants can look beyond their own patients for collective benefits of gaining insights from the rest of the network. Participants gain the ability to understand drug adoption and implementation, chart the speed and variation of adoption, highlight variations in patients’ access to anti-cancer medicines, provide insights into variations in practice and use of anti-cancer medicines, and create a stimulus for clinical research. Data collection is extracted directly from clinical systems.
Description
Start Date
Project Focus
- Regulator
Geographical Scope
- European
Keywords
- Cloud
Cloud Delivery Model
- PaaS
- SaaS
Project Life-Cycle Stage
- Operational Deployment
Industry
- Education and Skills
- Health
- Public Administration
Industry
- Science and Research
Technology
- Artificial Intelligence / Machine Learning
- Big Data